Insights into the Maturation Heterogeneity of Tumor-Associated Tertiary Lymphoid Structures in Cancer Immunotherapy
Wen Xu,Jianfeng Yang,Shiqi Ye,Wangrui Liu,Jiahe Lu,Aihetaimujiang Anwaier,Hailiang Zhang,Dingwei Ye
DOI: https://doi.org/10.2217/imt-2023-0196
2024-01-01
Immunotherapy
Abstract:ImmunotherapyAhead of Print EditorialInsights into the maturation heterogeneity of tumor-associated tertiary lymphoid structures in cancer immunotherapyWenhao Xu‡, Jianfeng Yang‡, Shiqi Ye‡, Wangrui Liu‡, Jiahe Lu, Aihetaimujiang Anwaier, Hailiang Zhang & Dingwei YeWenhao Xu‡ https://orcid.org/0000-0002-0660-9162Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, P.R. ChinaShanghai Genitourinary Cancer Institute, Shanghai, 200032, P.R. China‡Contribute equally to this workSearch for more papers by this author, Jianfeng Yang‡Department of Surgery, Pudong branch of Longhua Hospital, Shanghai University of Traditional Chinese Medicine, 1000 Shangnan Road, Shanghai, 200126, China‡Contribute equally to this workSearch for more papers by this author, Shiqi Ye‡Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, P.R. ChinaShanghai Genitourinary Cancer Institute, Shanghai, 200032, P.R. China‡Contribute equally to this workSearch for more papers by this author, Wangrui Liu‡Department of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, P.R. China‡Contribute equally to this workSearch for more papers by this author, Jiahe LuDepartment of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, P.R. ChinaShanghai Genitourinary Cancer Institute, Shanghai, 200032, P.R. ChinaSchool of Cellular & Molecular Medicine, University of Bristol, Bristol, BS8 1TD, UKSearch for more papers by this author, Aihetaimujiang AnwaierDepartment of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, P.R. ChinaShanghai Genitourinary Cancer Institute, Shanghai, 200032, P.R. ChinaSearch for more papers by this author, Hailiang Zhang *Author for correspondence: E-mail Address: zhanghl918@alu.fudan.edu.cnhttps://orcid.org/0000-0001-8408-7446Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, P.R. ChinaShanghai Genitourinary Cancer Institute, Shanghai, 200032, P.R. ChinaSearch for more papers by this author & Dingwei Ye **Author for correspondence: E-mail Address: dingwei_ye@fudan.edu.cnhttps://orcid.org/0000-0003-4974-3780Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, P.R. ChinaShanghai Genitourinary Cancer Institute, Shanghai, 200032, P.R. ChinaSearch for more papers by this authorPublished Online:19 Dec 2023https://doi.org/10.2217/imt-2023-0196AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: cancer immunotherapyimmune-infiltrating lymphocytestertiary lymphoid structurestumor microenvironmentPapers of special note have been highlighted as: • of interest; •• of considerable interestReferences1. Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19(6), 307–325 (2019). • This study underscores the growing significance of tertiary lymphoid structures (TLS) in tumor immunity due to its distinctive location and robust immune function. The integrated analysis strategy incorporating spatial and single-cell transcriptomics profoundly elucidates the immune mechanisms in tumors and their relevance to clinical immunotherapy by examining the unique structure, cellular composition and gene expression patterns within TLS. This approach is poised to substantially influence future research in the scientific field.Crossref, Medline, CAS, Google Scholar2. Domblides C, Rochefort J, Riffard C et al. Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation. Front. Immunol. 12, 698604 (2021).Crossref, Medline, CAS, Google Scholar3. Kinker GS, Vitiello GAF, Diniz AB et al. Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas. Gut 72(10), 1927–1941 (2023).Crossref, Medline, CAS, Google Scholar4. Munoz-Erazo L, Rhodes JL, Marion VC, Kemp RA. Tertiary lymphoid structures in cancer – considerations for patient prognosis. Cell Mol. Immunol. 17(6), 570–575 (2020).Crossref, Medline, CAS, Google Scholar5. Vanhersecke L, Brunet M, Guégan JP et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat. Cancer 2(8), 794–802 (2021). • The findings from this study highlight the predictive capability of TLS in determining the efficacy of immune checkpoint inhibitors, independent of PD-L1 expression, presenting robust evidence for the potential development of TLS-based predictive biomarkers. Furthermore, within mature TLS, the collaboration between B cells and dendritic cells is observed to enhance the training of CD8+ T cells by facilitating the transfer of tumor antibodies, underscoring the functional intricacies within the tumor microenvironment.Crossref, Medline, CAS, Google Scholar6. Posch F, Silina K, Leibl S et al. Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. Oncoimmunology 7(2), e1378844 (2018).Crossref, Medline, Google Scholar7. Fridman WH, Meylan M, Petitprez F, Sun CM, Italiano A, Sautès-Fridman C. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat. Rev. Clin. Oncol. 19(7), 441–457 (2022).Crossref, Medline, CAS, Google Scholar8. Meylan M, Petitprez F, Becht E et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 55(3), 527–541; e5 (2022).Crossref, Medline, CAS, Google Scholar9. Dieu-Nosjean MC, Giraldo NA, Kaplon H, Germain C, Fridman WH, Sautès-Fridman C. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol. Rev. 271(1), 260–275 (2016).Crossref, Medline, CAS, Google Scholar10. Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science 375(6576), eabf9419 (2022). •• The paper delves into an in-depth exploration of the current understanding of TLS in cancer, encompassing discussions on the underlying drivers of TLS formation, their pivotal function in shaping tumor immune responses, and their potential as a therapeutic target in human cancers.Crossref, Medline, CAS, Google Scholar11. Siliņa K, Soltermann A, Attar FM et al. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. Cancer Res. 78(5), 1308–1320 (2018). • A key milestone of this study lies in its pioneering identification of TLS maturity using multiple fluorescent markers to predict the prognosis and treatment response in patients with solid tumors. This work underscores the significance of TLS maturity heterogeneity as an essential factor in evaluating its clinical value, potentially revolutionizing prognostic assessments in the oncological landscape.Crossref, Medline, CAS, Google Scholar12. Allen E, Jabouille A, Rivera LB et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci. Transl. Med. 9(385), 1–28 (2017).Crossref, Google Scholar13. Sato Y, Silina K, van den Broek M, Hirahara K, Yanagita M. The roles of tertiary lymphoid structures in chronic diseases. Nat. Rev. Nephrol. 19(8), 525–537 (2023).Crossref, Medline, Google Scholar14. Ukita M, Hamanishi J, Yoshitomi H et al. CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. JCI Insight 7(12), 1–15 (2022).Crossref, Google Scholar15. Dai S, Zeng H, Liu Z et al. Intratumoral CXCL13(+)CD8(+)T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma. J. Immunother. Cancer 9(2), 1–10; e001823 (2021).Crossref, Google Scholar16. Truxova I, Kasikova L, Hensler M et al. Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. J. Immunother. Cancer 6(1), 139 (2018).Crossref, Medline, Google Scholar17. Asrir A, Tardiveau C, Coudert J et al. Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell 40(3), 318–334; e9 (2022).Crossref, Medline, CAS, Google Scholar18. Rodriguez AB, Peske JD, Woods AN et al. Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. Cell Rep. 36(3), 109422 (2021).Crossref, Medline, CAS, Google Scholar19. Xu W, Liu W, Yang J, Lu J, Zhang H, Ye D. Stimuli-responsive nanodelivery systems for amplifying immunogenic cell death in cancer immunotherapy. Immunol. Rev. doi: 10.1111/imr.13237 (2023) (Epub ahead of print).Crossref, Google Scholar20. Galluzzi L, Humeau J, Buqué A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol. 17(12), 725–741 (2020).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetails Ahead of Print STAY CONNECTED Metrics Downloaded 0 times History Received 16 August 2023 Accepted 17 November 2023 Published online 19 December 2023 Information© 2023 Future Medicine LtdKeywordscancer immunotherapyimmune-infiltrating lymphocytestertiary lymphoid structurestumor microenvironmentAuthor contributionsConceptualization: W Xu, W Liu, A Anwaier, J Lu and S Ye. Funding acquisition: W Xu, H Zhang and D Ye. Supervision: J Yang, H Zhang and D Ye. Original draft: W Xu, W Liu, A Anwaier and S Ye. Editing: H Zhang and D Ye.Financial disclosureThis work was supported by grants from the Shanghai Anticancer Association EYAS PROJECT (No. SACA-CY21A06 and SACA-CY21B01), and Shanghai Municipal Health Bureau (No.2020CXJQ03). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.Competing interests disclosureThe authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, stock ownership or options and expert testimony.Writing disclosureNo writing assistance was utilized in the production of this manuscript.PDF download